برنامج تطوير مهنة الصيدلة - PPDPROGRAM

➡️Tosymra (sumatriptan) Nasal Spray Date of Approval: January 25, 2019 Company: Dr. Reddy's Laboratories, Inc. Treatment for: Migraine Tosymra (sumatriptan) is a serotonin (5-HT1B/1D) receptor agonist (triptan) indicated for the acute treatment of migraine with or without aura in adults. https://t.me/ppdprogram

➡️Ontruzant (trastuzumab-dttb) for Injection Date of Approval: January 18, 2019 Company: Samsung Bioepis Co., Ltd. Treatment for: Breast Cancer, Gastric Cancer Ontruzant (trastuzumab-dttb) is a HER2/neu receptor antagonist biosimilar to Herceptin indicated for the treatment of HER2-overexpressing breast cancer, and the treatment of HER2-overexpressing metastatic gastric or gastroesophageal junction adenocarcinoma. https://t.me/ppdprogram

➡️Recorlev (levoketoconazole) Capsules Date of Approval: December 30, 2021 Company: Xeris Biopharma Holdings Treatment for: Cushing's Syndrome Recorlev (levoketoconazole) is a cortisol synthesis inhibitor indicated for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome https://t.me/ppdprogram

➡️Leqvio (inclisiran) Injection Date of Approval: December 22, 2021 Company: Novartis Treatment for: High Cholesterol, Familial Heterozygous Leqvio (inclisiran) is a small interfering RNA (siRNA) directed to PCSK9 (proprotein convertase subtilisin kexin type 9) mRNA used to reduce low-density lipoprotein cholesterol. https://t.me/ppdprogram

➡️Yusimry (adalimumab-aqvh) Injection Date of Approval: December 17, 2021 Company: Coherus BioSciences, Inc. Treatment for: Rheumatoid Arthritis, Juvenile Rheumatoid Arthritis, Psoriatic Arthritis, Ankylosing Spondylitis, Crohn's Disease, Ulcerative Colitis, Plaque Psoriasis Yusimry (adalimumab-aqvh) is a tumor necrosis factor (TNF) blocker biosimilar to Humira, approved for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, and plaque psoriasis. https://t.me/ppdprogram

➡️Vyvgart (efgartigimod alfa-fcab) Injection Date of Approval: December 17, 2021 Company: argenx SE Treatment for: Myasthenia Gravis Vyvgart (efgartigimod alfa-fcab) is a neonatal Fc receptor blocker indicated for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) antibody positive. https://t.me/ppdprogram

➡️Tezspire (tezepelumab-ekko) Injection Date of Approval: December 17, 2021 Company: Amgen and AstraZeneca Treatment for: Asthma Tezspire (tezepelumab-ekko) is a thymic stromal lymphopoietin (TSLP) blocker, human monoclonal antibody (IgG2λ), indicated for the add-on maintenance treatment of adult and pediatric patients aged 12 years and older with severe asthma. https://t.me/ppdprogram

➡️Dartisla ODT (glycopyrrolate) Orally Disintegrating Tablets Date of Approval: December 16, 2021 Company: Edenbridge Pharmaceuticals, LLC Treatment for: Peptic Ulcer Dartisla ODT (glycopyrrolate) is an anticholinergic indicated in adults to reduce symptoms of a peptic ulcer as an adjunct to treatment of peptic ulcer. https://t.me/ppdprogram

➡️Tarpeyo (budesonide) Delayed Release Capsules - formerly Nefecon Date of Approval: December 15, 2021 Company: Calliditas Therapeutics AB Treatment for: IgA Nephropathy Tarpeyo (budesonide) is a targeted release formulation of the approved corticosteroid budesonide indicated to reduce proteinuria in adults with primary immunoglobulin A nephropathy (IgAN). https://t.me/ppdprogram

➡️Xaciato (clindamycin phosphate) Vaginal Gel - formerly DARE-BV1 Date of Approval: December 7, 2021 Company: Daré Bioscience, Inc. Treatment for: Bacterial Vaginosis Xaciato (clindamycin phosphate) is a topical lincosamide antibacterial for the vaginally-administered treatment of bacterial vaginosis in female patients 12 years of age and older. https://t.me/ppdprogram

➡️Eprontia (topiramate) Oral Solution Date of Approval: November 5, 2021 Company: Azurity Pharmaceuticals, Inc. Treatment for: Epilepsy, Migraine Prevention Eprontia (topiramate) is a ready-to-use liquid formulation of the approved anticonvulsant topiramate for use in the treatment of epilepsy and the preventive treatment of migraine. https://t.me/ppdprogram

➡️Scemblix (asciminib) Tablets Date of Approval: October 29, 2021 Company: Novartis Treatment for: Chronic Myelogenous Leukemia Scemblix (asciminib) is a tyrosine kinase inhibitor used for the treatment of patients with Philadelphia chromosome-positive chronic myeloid leukemia (Ph+ CML). https://t.me/ppdprogram

➡️Tyrvaya (varenicline) Nasal Spray Date of Approval: October 15, 2021 Company: Oyster Point Pharma, Inc. Treatment for: Dry Eye Disease Tyrvaya (varenicline) is a nasally administered selective cholinergic agonist for the treatment of the signs and symptoms of dry eye disease. https://t.me/ppdprogram

➡️Zimhi (naloxone hydrochloride) Injection Date of Approval: October 15, 2021 Company: Adamis Pharmaceuticals Corporation Treatment for: Opioid Overdose Zimhi (naloxone hydrochloride) is a high-dose formulation of the approved opioid antagonist naloxone for use in the treatment of opioid overdose. https://t.me/ppdprogram

➡️Tavneos (avacopan) Capsules Date of Approval: October 7, 2021 Company: ChemoCentryx, Inc. Treatment for: ANCA-Associated Vasculitis Tavneos (avacopan) is a complement 5a receptor (C5aR) antagonist for the adjunctive treatment of anti-neutrophil cytoplasmic autoantibody (ANCA)-associated vasculitis. https://t.me/ppdprogram

➡️Qulipta (atogepant) Tablets Date of Approval: September 28, 2021 Company: AbbVie Inc. Treatment for: Migraine Prevention Qulipta (atogepant) is an oral, calcitonin gene-related peptide (CGRP) receptor antagonist indicated for the preventive treatment of episodic migraine in adults. https://t.me/ppdprogram

➡️Opzelura (ruxolitinib) Cream Date of Approval: September 21, 2021 Company: Incyte Treatment for: Atopic Dermatitis Opzelura (ruxolitinib) cream is a topical Janus kinase (JAK) inhibitor used for the treatment of atopic dermatitis. https://t.me/ppdprogram

➡️Tivdak (tisotumab vedotin-tftv) Lyophilized Powder for Injection Date of Approval: September 20, 2021 Company: Seagen Inc. Treatment for: Cervical Cancer Tivdak (tisotumab vedotin-tftv) is a tissue factor-directed antibody and microtubule inhibitor conjugate for the treatment of patients with recurrent or metastatic cervical cancer. https://t.me/ppdprogram

➡️Trudhesa (dihydroergotamine mesylate) Nasal Spray Date of Approval: September 2, 2021 Company: Impel NeuroPharma, Inc. Treatment for: Migraine Trudhesa (dihydroergotamine mesylate) is a nasally administered dihydroergotamine (DHE) formulation for the acute treatment of migraine with or without aura in adults. https://t.me/ppdprogram

➡️Skytrofa (lonapegsomatropin-tcgd) for Injection Date of Approval: August 25, 2021 Company: Ascendis Pharma A/S Treatment for: Pediatric Growth Hormone Deficiency Skytrofa (lonapegsomatropin-tcgd) is a human growth hormone used once-weekly for the treatment of pediatric growth hormone deficiency. https://t.me/ppdprogram